In vivo therapeutic efficacy of TNFα silencing by folate-PEG-chitosan-DEAE/siRNA nanoparticles in arthritic mice

Qin Shi1
Elsa-Patricia Rondon-Cavanzo1
Isadora Pfeifer Dalla Picola1,2
Marcio José Tiera2
Xiaoling Zhang3
Kerong Dai4
Houda Abir Benabdoune1
Mohamed Benderdour1
Julio Cesar Fernandes1
1Orthopedic Research Laboratory, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montréal, QC, Canada; 2Department of Chemistry and Environmental Sciences, UNESP-São Paulo State University, São José do Rio Preto, Brazil; 3Orthopedic Cellular and Molecular Biology Laboratories, Institute of Health Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, 4Department of Orthopedics, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Background: Tumor necrosis factor-alpha (TNFα), a pro-inflammatory cytokine, has been shown to play a role in the pathophysiology of rheumatoid arthritis. Silencing TNFα expression with small interfering RNA (siRNA) is a promising approach to treatment of the condition.

Methods: Towards this end, our team has developed a modified chitosan (CH) nanocarrier, deploying folic acid, diethylethylamine (DEAE) and polyethylene glycol (PEG) (folate-PEG-CH-DEAE14). The gene carrier protects siRNA against nuclease destruction, its ligands facilitate siRNA uptake via cell surface receptors, and it provides improved solubility at neutral pH with transport of its load into target cells. In the present study, nanoparticles were prepared with siRNA-TNFα, DEAE, and folic acid-CH derivative. Nanoparticle size and zeta potential were verified by dynamic light scattering. Their TNFα-knockdown effects were tested in a murine collagen antibody-induced arthritis model. TNFα expression was examined along with measurements of various cartilage and bone turnover markers by performing histology and microcomputed tomography analysis.

Results: We demonstrated that folate-PEG-CH-DEAE14/siRNA nanoparticles did not alter cell viability, and significantly decreased inflammation, as demonstrated by improved clinical scores and lower TNFα protein concentrations in target tissues. This siRNA nanocarrier also decreased articular cartilage destruction and bone loss.

Conclusion: The results indicate that folate-PEG-CH-DEAE14 nanoparticles are a safe and effective platform for non-viral gene delivery of siRNA, and their potential clinical applications warrant further investigation.

Keywords: arthritis, inflammation, siRNA, TNFα, nanoparticles, chitosan
Small interfering RNA (siRNA), a 19–21 nucleotide, double-stranded molecule, could represent an innovative therapeutic approach. This molecule (average molecular weight 13 kDa) is large and highly negative charged, and can poorly cross the cellular membranes which are also negatively charged, while also being highly homologous to nonspecific targets and very sensitive to RNase degradation. Therefore, an effective delivery system is needed to enclose siRNA in nanocarriers, protect it against nuclease destruction and transport it to tissues and cells of interest.

Different gene vectors, namely, viral and nonviral systems, have been studied for siRNA delivery because of their good properties as nonviral plasmid DNA delivery systems. CH (degree of deacetylation 85%) was purchased from Polymar Ciencia E Nutricao (Fortaleza, Brazil). Dulbecco’s Modified Eagle Medium, fetal bovine serum, 0.25% trypsin-EDTA solution, penicillin–streptomycin mixture and agarose were procured from Invitrogen Canada Inc. (Burlington, ON, Canada). Polyethylene glycol 2-aminoethyl ether acetic acid (NH₂-PEG-COOH), average Mn 3,500, folic acid and other chemicals, if not otherwise stated, were sourced from Sigma-Aldrich Chemical Co. (St Louis, MO, USA). In vivo presigned TNFα-targeted siRNA (250 nmol, GenBank accession number: NM_000594.3, Catalog No 4457308, siRNA ID No s202295) was obtained from Ambion Applied Biosystems (Carlsbad, CA, USA); sense 5’-CGU CGU AGC AAA CCA CCA ATT-3’, antisense 3’-UGG GUG GUU UGC UAC GAC GTG TG-5’. HeLa cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA).

Synthesis of folate-PEG-CH-DEAE conjugate
CH derivative (CH-DEAE₁₅, MW 241 kDa) was prepared from deacetylated CH, as described in our previous study. Folate conjugation with NH₂-PEG-COOH and folate-PEG conjugation with CH-DEAE₁₅ were processed as described by Cho et al, with minor modifications (refer to Scheme 1).

Nanoparticle preparation and characterization
Nanoparticles were produced on the basis of our previous results (unpublished data, Shi et al, Orthopedic Research Laboratory, Hôpital du Sacré-Cœur de Montréal, 2017). DEAE₁₅/CH and folate-PEG-CH-DEAE₁₅ were dissolved in HCl (0.1 M). Then, each solution was homogenized in a vortex mixer and heated at 50°C for 1 h. The process was repeated until the polymers were dissolved. For further dilution, 25 mM phosphate buffer (pH 6.3, ionic strength 50 mM) was included. The final concentration was 9.3 mM for each preparation, as previously described. Particle size and zeta potential were measured by Zetasizer Nano ZS90 (Malvern Instruments Ltd., Malvern, UK).

Cell viability
HeLa cells were seeded and transfected with free siRNA, CH-DEAE₁₅-siRNA or folate-PEG-CH-DEAE₁₅-siRNA complexes, followed by 24 h incubation. Cell viability was then evaluated by MTT colorimetric assay (Sigma-Aldrich Chemical Co.) based on MTT reduction by NAD(P)
H-dependent cellular oxidoreductase enzymes in viable cells to water-insoluble formazan. Absorbance was measured at 570 nm with an EL800 universal microplate reader (Bio-Tek Instruments Inc.).

CAIA model

The study comprised a total of 37 female, 8–12-week-old, DBA/1 mice (Jackson Laboratories, Bar Harbor, ME, USA), which were assigned to five experimental groups, each containing eight mice, except for one group which only had five members. Groups 1 and 2 represented normal and CAIA controls, respectively. Groups 3–5 were nanoparticle treated. All groups were conditioned and manipulated according to Canadian Council on Animal Care guidelines. This experimental protocol was adapted from previously reported methods and approved by the Research Ethics Committee of Hôpital du Sacré-Coeur de Montréal. Disease developed on days 4–5 and reached maximum on days 7–9. Simultaneously, on days 1, 3, 5 and 7, groups 3–5 received an intraperitoneal injection of DEAE\textsubscript{15}-CH/siRNA and folate-PEG-CH-DEAE\textsubscript{15}/siRNA, respectively, at 50 µg siRNA per administration. The normal and CAIA groups (groups 1 and 2, respectively) were given usual saline solution instead. Finally, all mice were sacrificed on day 10. Joint inflammation was measured by arthritic score\textsuperscript{22} on a scale of 0–4 for each paw (0 = normal, 1 = mild swelling, 2 = moderate swelling, 3 = severe swelling of entire paw, 4 = maximal inflammation),\textsuperscript{22} giving a total score of 0–16 for all four paws.

Ethics approval

This study was approved by the Animal Care Committee of the Hôpital du Sacré-Coeur de Montréal Research Centre, in accordance with Canadian Council on Animal Care guidelines. Protocol number: FERJ03.

Specimen selection

On day 10, the mice were anesthetized with isoflurane (3%), and blood was collected by cardiac puncture before euthanasia. Blood was centrifuged at 3,000 rpm for 10 min, and serum samples were stored at −80°C before use.\textsuperscript{36} Articular tissues (0.1 g) were harvested in 0.5 mL lysis buffer and processed by Precellys 24 Homogenizer, according to the manufacturer’s instructions. Homogenized tissues were centrifuged and the supernatants preserved and stored at −80°C.

TNFα protein levels

TNFα protein expression was assessed quantitatively with enzyme-linked immunosorbent assay kits from R&D Systems (Minneapolis, MN, USA), according to the manufacturer’s instructions. Mice TNFα protein levels were measured in articular homogenates and reactions were quantified by microplate reader (Molecular Devices Corp., Menlo Park, CA, USA). The detection limit of this assay was 10.9 pg/mL.

Serological marker of cartilage remodeling

As a marker of cartilage destruction, serum levels of degradation products of C-terminal telopeptide type II collagen (CTX-II) were assessed by Serum Pre-Clinical CartLaps enzyme-linked immunosorbent assay kit from IDS Ltd. (Boldon, Tyne and Wear, UK), according to the manufacturer’s instructions. The detection limit of this assay was 1.2 pg/mL.

Scheme 1 Synthetic scheme for the synthesis of the folic acid-labeled diethylethylamine-chitosan.

Abbreviations: CH, chitosan; DCC, dicyclohexylcarbodiimide; DEAE, diethylethylamine; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; FA, folic acid; NHS, N-hydroxysuccinimide; PEG, polyethylene glycol.
Serological markers of bone remodeling
Alkaline phosphatase (ALP), osteocalcin (OC) and procollagen I N-terminal peptide (PINP) are considered to be biomarkers of bone formation.\textsuperscript{37} Serum ALP activity was quantified as described in a previous study.\textsuperscript{18} Nascent serum OC levels were analyzed by specific enzyme immunoassay (Biomedical Technologies, Inc., Stoughton, MA, USA), according to the manufacturer’s instructions. The detection limit of this assay was 0.4 ng/mL.\textsuperscript{25} Serum PINP was quantified by rat/mouse PINP EIA immunoassay kit from IDS Ltd. The detection limit of this assay was 0.7 ng/mL.

Histologic examination and immunohistochemistry
Whole knee joint sections were fixed in 10\% (v/v) formalin and decalcified with 10\% (v/v) formic acid for 24 h. The specimens were embedded in paraffin, sectioned, and stained with hematoxylin–eosin,\textsuperscript{25} safranin O and toluidine blue, respectively. Three sections were examined by digital EVOS light microscopy (Electron Microscopy Sciences, Hatfield, PA, USA) at 20× magnification to evaluate synovitis, bone erosion and cartilage damage. A scoring system, consisting of three grades per condition, as described by Bas et al.,\textsuperscript{39} was employed by two investigators blinded to origin of the samples. Synovial inflammation scores were assigned as: 0: no inflammation, 1: slight thickening of the synovial layer and/or some inflammatory cells in the sub-lining, 2: moderate infiltration of the sub-lining and 3: marked-to-severe infiltration. Bone erosion scores were as follows: 0: normal bone, 1: small resorption areas, 2: numerous resorption areas and 3: full thickening of bone resorption areas. Cartilage destruction scores were as follows: 0: normal cartilage, 1: cartilage surface irregularities, 2: minor-to-moderate loss of surface cartilage and 3: marked cartilage destruction with loss of surface cartilage.\textsuperscript{39} Tissue sections stained with toluidine blue were evaluated for proteoglycan to estimate cartilage structure condition.\textsuperscript{40}

TNF\(\alpha\) detection in knee tissues by immunohistochemistry
Immunohistochemistry included rabbit monoclonal anti-TNF\(\alpha\) (diluted 1:1,000; HP8001, rabbit IG; Hycult Biotechnology BV, Uden, the Netherlands). The section of TNF\(\alpha\) was developed with Dako EnVision + Dual Link System-HRP (DAB+) kit (Dako, Glostrup, Denmark). Counterstaining involved hematoxylin, and rabbit IgG served as negative control. Briefly, three sections from each femoral condyle and tibial plateau were scored by two investigators blinded to origin of the samples. Total and positively stained chondrocytes were counted and reported as percentages, where 100\% was the maximum score.\textsuperscript{41}

Osteoclast activity was observed by tartrate-resistant acid phosphatase (TRAP) staining with leukocyte acid phosphatase kits (Sigma-Aldrich Chemical Co.) following the manufacturer’s instructions. Nuclei were counterstained with Gill’s hematoxylin (Sigma-Aldrich Chemical Co.), and averages of TRAP-positive osteoclasts were calculated.\textsuperscript{25}

Bone assessment and micro-CT analysis
Mice left hind limbs, from the hip joint to the ankle, were fixed with 4\% paraformaldehyde for three-dimension (3D) micro-CT analysis. Samples were subjected to Skyscan 1176-High Resolution in vivo X-Ray Microtomography (Bruker-MicroCT, Kontich, Belgium) at 50 kVp and 500 \(\mu\)A (http://www.skyscan.be/products/1176.htm). The parameters mentioned below were analyzed according to the procedure described by Ibanez et al.\textsuperscript{42} Trabecular bone microarchitecture of the femur was assessed by morphometric indices, such as bone volume/tissue volume (BV/TV, \%), trabecular bone thickness (TbTh, mm), trabecular number (TbN, 1/mm) and trabecular separation (TbSp, mm). Cortical bone was evaluated by bone mineral density (BMD) index (g/cm\(^3\)).

Statistical analysis
The data are expressed as means ± standard error of the means of five to eight mice. All statistics were generated by Prism software (GraphPad Software, San Diego, CA, USA). Statistical significance was assessed by unpaired Student’s \(t\)-test, and \(P<0.05\) values were deemed to be significant.\textsuperscript{25}

Results
Nanoparticle characterization
The sizes of synthesized nanoparticles were 259±3 nm for CH-DEAE\(_{12}\)/siRNA with a zeta potential of +28.3±0.8 mV, and 233±21 nm for folate-PEG-CH-DEAE\(_{12}\)/siRNA with a zeta potential of +34.8±1.4 mV. Nanoparticle N/P ratio was 2 (\(N = \) polymer amine groups, \(P = \) siRNA phosphate groups).

Cell viability
The average cell viability of free siRNA or nanoparticle-treated cells was 89\%–97\% compared to nontreated cells (100\%; Figure 1). This result shows no change in cell viability with our synthesized CH-based nanoparticles. These findings indicate that our nanoparticles at the tested dose are safe in cultured cells.
Assessment of disease activity and progression

Arthritis score (Figure 2A and B) and hind paw edema (Figure 2C and D) were evaluated with arthritis severity scores22 and digital caliper, respectively. Arthritis developed on day 4, and maximum inflammation was observed between days 7 and 10 (Figure 2A and E). Untreated CAIA mice (group 2) presented progressive arthritis characterized by distinctive redness or inflammation of the limb joints (Figure 2A, C and E) consistent with paw swelling (Figure 2C and D). Clinical arthritis scores on day 10 were significantly less severe in group 4 (folate-PEG-CH-DEAE15/siRNA-TNFα; Figure 2B). Paw thickness increased significantly in CAIA (group 2) mice on day 10 (Figure 2D and E) and decreased significantly in group 4. See Table 1 for detailed outcomes. Altogether, our data clearly show that our nanoparticles have antiarthritic properties through reducing the disease activity and scoring.

Histopathologic changes in knee joints

Knee sections from normal mice (group 1) did not show any histopathologic changes (Figure 3A, left panel). CAIA mice (group 2) displayed marked synovitis (Figure 3A and B), bone loss in tibia and femur sections (Figure 3A and C) as well as cartilage destruction (Figure 3A and D). Knee joints from the folate-PEG-CH-DEAE15/siRNA-TNFα group (4) displayed similar to regular cartilage lining, disclosing significant cartilage improvement (Figure 3A and D), significant prevention of bone destruction (Figure 3C) and significant reduction of joint pathology (synovitis), compared to CAIA mice (group 2), as described in Table 2.

Cartilage remodeling

Articular cartilage staining was strong in normal mice (group 1; Figure 3A, middle and right panels), as opposed to the weak or absent cartilage staining in CAIA mice (group 2). Folate-PEG-CH-DEAE15/siRNA-TNFα treatment (group 4) improved cartilage appearance (Figure 3A, middle and right panels). Serum CTX-II concentrations were assessed to quantify cartilage remodeling of mice knees (Table 2). This biomarker gives evidence of articular cartilage condition by predicting its degradation rate.43 By day 10, serum CTX-II levels had increased significantly in CAIA mice (Figure 3E), whereas they were significantly reduced in folate-PEG-CH-DEAE15/siRNA-TNFα-treated mice relative to arthritic (CAIA) group 2, and were comparable to normal mice. Collectively, our results strongly suggest that our synthesized CH-nanoparticles protect the bone and cartilage in our experimental model of arthritis from structural damages.

Proinflammatory cytokine TNFα profile of joints

The potential therapeutic effect of folate-PEG-CH-DEAE15/siRNA-TNFα nanoparticles on TNFα concentrations was evaluated in knee tissues, estimating the efficacy of this approach in controlling TNFα expression and its potential impact in RA. TNFα levels in affected knee tissues were significantly higher in CAIA (group 2) compared to the normal (group 1) controls (Figure 4A). TNFα values were significantly decreased in folate-PEG-CH-DEAE15/siRNA-TNFα-treated mice (group 4) relative to arthritic group 2 (Table 2). Immunohistochemistry of knee cartilage revealed considerably stronger TNFα staining in CAIA mice (group 2; Figure 4B) than in normal controls (group 1) and folate-PEG-CH-DEAE15/siRNA-TNFα–treated mice (group 4). The number of TNFα-positive cells in articular tissues (black arrows, Figure 4B) returned to normal in group 4 (Figure 4B and C). Taken together, our data confirm the anti-inflammatory properties of CH-nanoparticles in arthritic mice.

Micro-CT analysis of periarticular bone in knee joints

The impact of folate-PEG-CH-DEAE15/siRNA-TNFα treatment on bone destruction was evaluated by 3D micro-CT analysis in CAIA mice. The results showed reduced

![Cell viability graph](image)

**Figure 1** CH-based nanoparticles did not affect cell viability.

**Notes:** HeLa cells were treated for 24 h with 5 μg free siRNA-TNFα, CH-DEAE15, CH-siRNA-TNFα or folate-PEG-CH-DEAE15/siRNA-TNFα complexes containing an equivalent of 5 μg siRNA-TNFα. Cell viability was evaluated by MTT assay. The results were compared by paired Student’s t-test and expressed as means ± SEM for n=3.

**Abbreviations:** CH, chitosan; DEAE, diethylammonium; PEG, polyethylene glycol; SEM, standard error of the means; TNFα, tumor necrosis factor-alpha.
Figure 2 Arthritis progression and the therapeutic effects of CH-DEAE/siRNA-TNFα, folate-PEG-CH-DEAE/siRNA-TNFα and naked siRNA-TNFα nanoparticles in a murine CAIA model.

Notes: (A) Joint inflammation in mice was measured by an arthritic scoring method to verify disease progression on a scale of 0–4 for each paw, for a total score of 0–16 for all four paws. On the first day (day 1), arthritis was induced by ip injection of a 1.5 mg cocktail of arthritogenic mAb against type II collagen. Two days later (day 3), mice received an ip injection with 50 µg Escherichia coli (0.5 mg/mL stock) lipopolysaccharide. At the same time on days 1, 3, 5 and 7, mice received an ip injection with 100 µL of nanoparticles containing the equivalent of 50 µg siRNA-TNFα. (B) Arthritic score on day 10. (C) Arthritis development estimated by measuring hind paw thickness over the course of the experiment. (D) Hind paw thickness on day 10. (E) Hind paws of mice on day 10. Statistical significance was assessed by unpaired Student’s t-test, *P < 0.05, ***P < 0.001. Each group contained eight mice except group 5 which only had five mice. Group 1: normal control; group 2: CAIA control; group 3: CAIA mice treated with CH-DEAE/siRNA-TNFα nanoparticles; group 4: CAIA mice treated with folate-PEG-CH-DEAE/siRNA-TNFα nanoparticles; group 5: CAIA mice treated with siRNA-TNFα.

Abbreviations: CAIA, collagen antibody-induced arthritis; CH, chitosan; DEAE, diethylethylamine; ip, intraperitoneal; mAb, monoclonal antibody; ND, not determined; PEG, polyethylene glycol; SEM, standard error of the means; TNFα, tumor necrosis factor-alpha.
trabecular bone (Figure 5A), lower cortical BMD (Figure 5B) and BV\% (Figure 5C), with decreased TbSp (Figure 5F) in CAIA mice (group 2), whereas TbTh (Figure 5D) and TbN (Figure 5E) remained unchanged, compared to normal controls. The significant diminution of BV/TV (Figure 5C) in CAIA mice (group 2) indicates marked bone loss in the trabecular region of the tibia compared to the controls (group 1). Folate-PEG-CH-DEAE\_15/siRNA-TNF\_α treatment (group 4) increased tibia cortical BMD compared to CAIA mice (group 2, P=0.133; Figure 5B). In addition, it restored the trabecular thickness loss observed in CAIA mice. The parameters TbN (Figure 5E) and TbSp (Figure 5F) remained unchanged after treatment compared to the CAIA group (group 2). These findings are in accordance with those of histologic analysis and confirm the protective effect of CH-nanoparticle against bone loss in arthritic mice.

**Discussion**

Gene knockdown by siRNA has been gaining interest in the framework of gene therapy. Modified CH nanocarriers have been considered as effective platforms to enclose and deliver plasmid DNA and siRNA in vitro,24,46,47 and in vivo.22 In this study, CH was modified with DEAE groups and folic acid-targeting ligands. DEAE ligands increased the colloidal stability of CH nanoparticles because of their hydrophilicity and capacity to stay protonated in part under physiological conditions.28 Uptake efficiency may be enhanced by achieving balance between interaction strengths and augmented colloidal stability.28,29 To date, no in vivo folate-PEG-CH-DEAE\_15/siRNA-based therapy of arthritis and other musculoskeletal disorders has been developed.

A murine RA model was tested in this study to evaluate the efficacy of folate-PEG-CH-DEAE\_15/siRNA-TNF\_α nanoparticles. This approach can significantly decrease inflammation-induced articular cartilage damage and bone destruction, as indicated by TNF\_α protein reduction in affected arthritic tissues. We chose the murine CAIA model because of its rapid disease onset,10 which occurs within a few days and resembles the RA seen in humans.1 The therapeutic effects of folate-PEG-CH-DEAE\_15/siRNA nanoparticles targeting TNF\_α demonstrated significant inhibition of inflammation in comparison to untreated controls (Figure 2).

Experimental evidence suggests that functional blockade of TNF\_α controls CAIA development.3 We hypothesized that TNF\_α knockdown, with folate-CH nanocarriers, could
Figure 3  Histologic examination and cartilage destruction marker.

Notes: (A) Hematoxylin–eosin-, safranin O- and toluidine blue-stained images of the hind knee joints of mice from different groups. Knee sections were fixed, sectioned, stained and finally observed by light microscopy at 20× magnification. Severity scores of (B) synovitis, (C) bone erosion and (D) cartilage destruction were assessed on day 10 by two investigators blinded to origin of the samples and using the already-described scoring method. (E) Serum levels of CTX-II degradation products measured by ELISA. Values are the means ± SEM of eight mice (groups 1–4) and five mice (group 5). Statistical significance was assessed by unpaired Student’s t-test, *P<0.05, **P<0.01. Group 1: normal control; group 2: CAIA control; group 3: CAIA mice treated with CH-DEAE/sirNA-TNFα nanoparticles; group 4: CAIA mice treated with folate-PEG-CH-DEAE/sirRNA-TNFα nanoparticles; group 5: CAIA mice treated with sirNA-TNFα.

Abbreviations: CAIA, collagen antibody-induced arthritis; CH, chitosan; CTX-II, C-terminal telopeptide type II collagen; DEAE, diethylethylamine; ELISA, enzyme-linked immunosorbent assay; ND, not determined; PEG, polyethylene glycol; SEM, standard error of the means; TNFα, tumor necrosis factor-alpha.
Table 2 Histologic examination scores, CTX-II and TNFα levels

| Synovities score (0–3) | Bone erosion score (0–3) | Cartilage destruction score (0–3) | Serum CTX-II (pg/mL) | Knee TNFα (pg/mL) | TNFα+ cells (%) |
|------------------------|--------------------------|----------------------------------|----------------------|------------------|-----------------|
| Group 1                | 0.0                      | 0.0                              | 0.0                  | 3.98±1.21        | 7.19±0.36       | 30.53±2.59      |
| Group 2                | 3.00±0.01                | 3.00±0.01                        | 2.94±0.06            | 8.90±1.27        | 13.08±0.80      | 64.48±3.11      |
| Group 3                | 2.68±0.31                | 2.56±0.20                        | 2.50±0.25            | 8.68±2.50        | 10.38±0.77      | 61.05±4.36      |
| Group 4                | 1.93±0.37                | 1.81±0.38                        | 1.56±0.44            | 3.67±1.15        | 9.78±0.90       | 33.04±5.14      |
| Group 5                | 2.98±0.01                | 2.66±0.33                        | 2.33±0.33            | 8.80±2.80        | 11.39±1.34      | 63.08±3.74      |

Notes: Group 1: normal control; group 2: CAIA control; group 3: CH-DEAE/siRNA-TNFα-treated mice; group 4: folate-PEG-CH-DEAE/siRNA-TNFα-treated mice; group 5: siRNA-TNFα-treated mice. The data are expressed as means ± SEM. Groups 1–4: eight mice each; group 5: five mice. *P<0.05 compared to normal mice. **P<0.01 compared to normal mice. ***P<0.001 compared to normal mice. *P<0.05 compared to CAIA mice. **P<0.01 compared to CAIA mice. ***P<0.001 compared to CAIA mice. "P<0.05 compared to group 4. "P<0.01 compared to group 4.

Abbreviations: CAIA, collagen antibody-induced arthritis; CH, chitosan; CTX-II, C-terminal telopeptide type II collagen; DEAE, diethylethylamine; PEG, polyethylene glycol; SEM, standard error of the means; TNFα, tumor necrosis factor-alpha.

Figure 4 TNFα expression.

Notes: (A) TNFα concentrations were determined by ELISA in tissue homogenates of knee joints. (B) Immunostaining of TNFα-positive chondrocytes (black arrows). (C) Total and positive-stained chondrocytes were counted and presented as percentages. Values are the means ± SEM of eight mice (groups 1–4) and five mice (group 5). Statistical significance was assessed by unpaired Student’s t-test, *P<0.05, **P<0.01, ***P<0.001. Group 1: normal control; group 2: CAIA control; group 3: CAIA mice treated with CH-DEAE/siRNA-TNFα nanoparticles; group 4: CAIA mice treated with folate-PEG-CH-DEAE/siRNA-TNFα nanoparticles; group 5: CAIA mice treated with siRNA-TNFα.

Abbreviations: CAIA, collagen antibody-induced arthritis; CH, chitosan; CTX-II, C-terminal telopeptide type II collagen; DEAE, diethylethylamine; ELISA, enzyme-linked immunosorbent assay; PEG, polyethylene glycol; SEM, standard error of the means; TNFα, tumor necrosis factor-alpha.
downregulate TNFα expression and the arthritic outcome in a murine CAIA model. We included folic acid groups because folate receptors are overexpressed on activated macrophages, playing a role in the inflammatory conditions seen in RA.\textsuperscript{48,49} Folic acid ligands increased CH/siRNA complex treatment efficiency in murine CAIA, which confirms our previous findings on an adjuvant-induced arthritis model.\textsuperscript{25}

Folate-PEG-CH-DEAE/siRNA-TNFα treatment significantly decreased arthritis, as indicated by clinical scores in comparison to normal and CAIA mice (Figure 2). Reduction of this arthritic condition was due to downregulation of TNFα expression in knee tissues, where its inhibition was evidenced by lining level (group 4; Figure 4). These results support the outcomes of other experimental studies, where TNFα knockdown controlled RA pathology.\textsuperscript{2,22,30} TNFα silencing with peptide/siRNA complexes and CH/siRNA nanoparticles decreased joint pathology in CAIA and collagen-induced arthritis (CIA) models, respectively.\textsuperscript{2,22} TNFα knockdown with monoclonal antibodies also had good outcomes in murine CIA\textsuperscript{6} and is being used to treat patients.\textsuperscript{51} One potential pitfall of therapies involving TNFα monoclonal antibodies is the heightened risk of immune system impairment.\textsuperscript{52,53} In this respect, folate-CH nanoparticles offer the advantage of targeting folate receptors on activated cells, which decreases TNFα expression in affected tissues rather than in serum, lowering systemic risk.

Nontreated CAIA mice showed cartilage and bone destruction. Cartilage destruction was measured by quantifying serum CTX-II. Levels of the cartilage destruction marker were

![Figure 5](Continued)
lower in CAIA mice treated with folate-PEG-CH-DEAE_{15}/siRNA-TNFα nanoparticles than in nontreated CAIA mice (group 2), reflecting decreased joint cartilage destruction in these animals (Figure 3E). They also reflect macroscopic scores and histologic evidence (Figure 3A). The histologic findings demonstrated that all joints from CAIA mice without treatment had synovitis and cartilage structure abnormalities, such as surface fissures and loss of cells, while cartilage surfaces in normal mice were regular and contained abundant cells. Folate-PEG-CH-DEAE_{15}/siRNA-TNFα (group 4) successfully improved synovitis, bone erosion and cartilage destruction scores of joint pathology in CAIA mice (Figure 3B–D).

Bone remodeling is a process where osteoclast and osteoblast activities are synchronized to resorb old bone and synthesize new bone matrix, respectively.\textsuperscript{54,55} Bone destruction is a typical characteristic of advanced RA.\textsuperscript{5,44} Inflammation

---

**Figure 5** Micro-CT analysis. **Notes:** (A) Representative trabecular bone in micro-CT images of the distal femur in mice from different groups. (B) Cortical BMD in femur diaphysis. (C) Trabecular bone volume as percentage of total volume (BV/TV). (D) TbTh. (E) TbN. (F) TbSp. n=3. Values are the means ± SEM of three mice. Statistical significance was assessed by unpaired Student’s t-test, *P<0.05, **P<0.01, ***P<0.001. Group 1: normal control; group 2: CAIA control; group 3: CAIA mice treated with CH-DEAE/siRNA-TNFα nanoparticles; group 4: CAIA mice treated with folate-PEG-CH-DEAE/siRNA-TNFα nanoparticles; group 5: CAIA mice treated with siRNA-TNFα.

**Abbreviations:** BMD, bone mineral density; BV, bone volume; CAIA, collagen antibody-induced arthritis; CH, chitosan; CTX-II, C-terminal telopeptide type II collagen; DEAE, diethylethylamine; ELISA, enzyme-linked immunosorbent assay; micro-CT, micro-computed tomography; PEG, polyethylene glycol; SEM, standard error of the means; TbN, trabecular bone number; TbSp, trabecular separation; TbTh, trabecular bone thickness; TNFα, tumor necrosis factor-alpha; TV, tissue volume.
can generate inequality between both bone remodeling processes. ALP, PINP and OC biomarkers were measured to assess bone formation. ALP is a membrane protein the bonespecific form of which is known to be a biochemical marker of bone formation. PINP is a propeptide found in blood during type I collagen synthesis, providing proof of the bone matrix formation process. OC is a protein synthesized by osteoblasts. Its presence in blood indicates that a part of OC does not bind to the bone matrix during bone formation or may reflect its release from the bone matrix during bone resorption. Serum OC levels are high in bone diseases, characterized by high bone turnover. OC may be important in recruiting and activating bone-resorbing cells.

Our data demonstrated that serum ALP and PINP levels decreased in arthritic mice (group 2; Figure 6A and C), suggesting ongoing reduction of bone formation due to inflammation-induced bone destruction. These outcomes support previous findings where serum ALP and PINP levels decreased significantly, while serum OC levels increased in postmenopausal CIA mice. In this study, folate-PEG-CH–treated mice (group 4) showed reduced serum TRAP levels compared to arthritic mice (group 2; Figure 6D). Histochemical staining of mice joint sections disclosed that TRAP activity corresponded to abundance of TRAP-positive osteoclasts observed in arthritic tissues (group 2) where bone damage was evident (Figure 6E and F). The folate-CH group showed lower numbers of TRAP-positive cells and improved the bone structure (Figure 6E). These outcomes support previous findings in a study of adjuvant-induced arthritis rats.

TNFα downregulation reduces inflammation and osteoporosis, the latter by decreasing osteoclast recruitment and activation, hence the resorptive effect. TNFα has also been recognized to activate and increase RANKL production, which has an impact on osteoclast formation. This cytokine influences osteoclast and osteoblast osteogenesis. For this reason, bone structure analysis is imperative to study the efficacy of anti-TNFα therapy. Bone microarchitecture is one of the parameters used to evaluate bone strength.
**Figure 6** Biomarkers of bone formation and resorption.

**Notes:** Therapeutic effect of CH-DEAE<sub>15</sub>/sirNa-TNF<sub>α</sub>, folate-Peg-ch-DEAE<sub>15</sub>/sirNa-TNF<sub>α</sub>, and naked sirNa-TNF<sub>α</sub> nanoparticles on serum bone marker levels in CAIA mice. (A) Serum ALP on day 10. (B) Serum OC on day 10. (C) Serum PINP on day 10. (D) Serum TRAP levels. (E) Immunostaining showing TRAP-positive cells indicated by black arrows. (F) Percentage of TRAP-positive cells in each group. Statistical significance was assessed by unpaired Student’s t-test. *P<0.05, **P<0.01, ***P<0.001. Group 1: normal control; group 2: CAIA control; group 3: CAIA mice treated with DEAE<sub>15</sub>-ch/sirNa-TNF<sub>α</sub> nanoparticles; group 4: CAIA mice treated with folate-Peg-ch-DEAE<sub>15</sub>/sirNa-TNF<sub>α</sub> nanoparticles; group 5: CAIA mice treated with sirNa-TNF<sub>α</sub>.

**Abbreviations:** ALP, alkaline phosphatase; CAIA, collagen antibody-induced arthritis; CH, chitosan; CTX-II, C-terminal telopeptide type II collagen; DEAE, diethylethylamine; ELISA, enzyme-linked immunosorbent assay; OC, osteocalcin; PEG, polyethylene glycol; PINP, procollagen I N-terminal peptide; SEM, standard error of the means; TNF<sub>α</sub>, tumor necrosis factor-alpha; TraP, tartrate-resistant acid phosphatase.

|              | Serum ALP (nmol/60 min) | Serum PINP (ng/mL) | Serum OC (ng/mL) | Serum TRAP (U/L) | TRAP<sup>+</sup> cells (%) |
|--------------|-------------------------|--------------------|------------------|-----------------|--------------------------|
| Group 1      | 1.54±0.08               | 2.41±0.30          | 73.02±10.64      | 10.66±4.28      | 18.67±1.65              |
| Group 2      | 0.87±0.04               | 2.19±0.38          | 125.3±11.41      | 210.8±42.67     | 79.80±8.53              |
| Group 3      | 0.99±0.08               | 3.24±0.76          | 133.6±18.8       | 173.3±31.71     | 59.33±4.75              |
| Group 4      | 1.23±0.11               | 4.40±0.85          | 78.98±14.90      | 136.7±23.80     | 26.69±2.95              |
| Group 5      | 1.00±0.11               | 2.47±0.29          | 84.28±6.92       | 188.3±11.56     | 67.50±8.37              |

**Notes:** Group 1: normal control; group 2: CAIA control; group 3: CH-DEAE<sub>15</sub>/sirNa-TNF<sub>α</sub>-treated mice; group 4: folate-PEG-CH-DEAE<sub>15</sub>/sirNa-TNF<sub>α</sub>-treated mice; group 5: sirNa-TNF<sub>α</sub>-treated mice. The data are expressed as means ± SEM. Groups 1–4: eight mice each; group 5: five mice. *P<0.05 compared to normal mice. **P<0.01 compared to normal mice. ***P<0.001 compared to normal mice. *P<0.05 compared to CAIA mice. **P<0.01 compared to CAIA mice. ***P<0.001 compared to CAIA mice.

**Abbreviations:** ALP, alkaline phosphatase; CAIA, collagen antibody-induced arthritis; CH, chitosan; DEAE, diethylethylamine; OC, osteocalcin; PEG, polyethylene glycol; PINP, procollagen I N-terminal peptide; SEM, standard error of the means; TNF<sub>α</sub>, tumor necrosis factor-alpha; TraP, tartrate-resistant acid phosphatase.
and, in this investigation, it was verified by 3D micro-CT analysis. Our results showed significant bone loss and structural alterations on day 10 in CAIA mice (group 2), based on significant reduction of cortical BMD (Figure 5B) and BV/TV (Figure 5C), compared to the normal controls (group 1). Interestingly, animals treated with folate-PEG-CH-DEAE\textsubscript{15}/siRNA-TNF\textalpha nanoparticles maintained bone quality (improved cortical BMD and increased TbTh in a significant way in comparison to CAIA mice; Figure 5B and D). Enhancement of bone parameter outcomes by folate-CH nanocarriers was supported by decreased bone erosion scores (Figure 3C) and bone metabolism markers (Figure 5).

**Conclusion**

In conclusion, TNF\textalpha silencing by folate-PEG-CH-DEAE\textsubscript{15}/siRNA nanoparticles is a potentially new approach to RA treatment. The results obtained in this study support previous findings on the capacity of folate-targeted CH-siRNA/DNA nanoparticles to control inflammation as well as bone and cartilage destruction.

**Acknowledgments**

The authors thank Dr Daniel Lajeunesse (Université de Montréal) for his critical review of the manuscript, Ms Caroline Bouchard for animal handling-treatment and Mr Ovid Da Silva for manuscript editing. This work was supported, in part, by grants from the Science and Technology Commission of Shanghai Municipality (No 16430723500), Ministère de l’Économie, de la Science et de l’Innovation du Québec (Programme de soutien à la recherche [PSR], volet 4: Soutien à des initiatives internationales de recherche et d’innovation [SIIRI], 2017–2020), Canadian Institutes of Health Research (CCM 104888), and CNPq (grant 407499/2013-0). This study was conducted in Montréal, QC, Canada, and São Jose do Rio Preto, SP, Brazil.

**Availability of data and materials**

Supporting data are available as the authors have full access to all study data.

**Disclosure**

JCF, MJT, QS, MB and IPDP have filed for a patent on the nanoparticles described in this study. The authors report no other conflicts of interest in this work.

**References**

1. Asquith DL, Miller AM, Mclnnes IB, et al. Animal models of rheumatoid arthritis. *Eur J Immunol*. 2009;39(8):2040–2044.

2. Ye C, Bhan A, Deshpande V, et al. Silencing TNF-\textalpha in macrophages and dendritic cells for arthritis treatment. *Scand J Rheumatol*. 2013;42(4):266–269.

3. Marenzana M, Vugler A, Moore A, Robinson M. Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study. *Arthritis Res Ther*. 2013;15(5):R125.

4. Scott D. Prognostic factors in early rheumatoid arthritis. *Rheumatology (Oxford, England)*. 2000;39:24–29.

5. Goldring SR, Gravallese EM. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. *Arthritis Res*. 2000;2(1):33–37.

6. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. *Proc Natl Acad Sci U S A*. 1992;89(20):9784–9788.

7. Paquet J, Henriotton C, Pinzano A, et al. Alternative for anti-TNF antibodies for arthritis treatment. *Mot Ther*. 2011;19(10):1887–1895.

8. Buch MH, Pavitt S, Parmar M, Emery P. Creative trial design in RA: optimizing patient outcomes. *Nat Rev Rheumatol*. 2013;9(3):183–194.

9. van Schouwenburg PA, Rispens T, Woblink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. *Nat Rev Rheumatol*. 2013;9(3):164–172.

10. Bender AT, Spyvee M, Satoh T, et al. Evaluation of a candidate antiarthritic drug using the mouse collagen antibody induced arthritis model and clinically relevant biomarkers. *Am J Transl Res*. 2013;5(1):92.

11. Mehta G, Scheinman RJ, Holers VM, Banda NK. A new approach for the treatment of arthritis in mice with a novel conjugate of an anti-C5aR1 antibody and C5 small interfering RNA. *J Immunol*. 2015;194(11):5446–5454.

12. Hamamura K, Nishimura A, Chen A, et al. Salubrinial acts as a Dusp2 inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis. *Cell Signal*. 2015;27(4):828–835.

13. Schifferles RM, Xu J, Storm G, et al. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. *Arthritis Rheum*. 2005;52(4):1314–1318.

14. Shi Q, Tiera MJ, Zhang X, et al. Chitosan-DNA/siRNA nanoparticles for gene therapy. *Non-Viral Gene Ther*. 2011;19:455–480.

15. Tiera MJ, Shi Q, Barbosa HF, Fernandes JC. Polymeric systems as nanodevices for siRNA delivery. *Curr Gene Ther*. 2013;13(5):358–369.

16. Xiang S, Su J, Tong H, et al. Biscarbamate cross-linked low molecular weight PEI for delivering IL-1 receptor antagonist gene to synovioocytes for arthritis therapy, *Biomaterials*. 2012;33(27):6520–6532.

17. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. *Nature*. 2009;457(7228):426–433.

18. Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. *J Control Release*. 2007;121(1–2):64–73.

19. Gao X, Kim KS, Liu D. Nonviral gene delivery: what is next. *Proc Natl Acad Sci U S A*. 2000;97(13):6655–6659.

20. Andersen MO, Howard KA, Kjens J. DNA/RNAi complexes and dendritic cells for arthritis treatment. *J Control Release*. 2013;179(1–2):64–73.

21. Haque M, Bouchard J, McInnes IB, et al. Animal models of rheumatoid arthritis: a review. *Arthritis Rheum*. 2006;54(4):1212–1222.

22. Andersen MO, Howard KA, Kjens J. DNA/RNAi complexes and dendritic cells for arthritis treatment. *J Control Release*. 2013;179(1–2):64–73.
25. Fernandes JC, Wang H, Jreysatay C, et al. Bone-protective effects of nonviral gene therapy with Folate–Chitosan DNA nanoparticle containing Interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. *Mol Ther*. 2008;16(7):1243–1251.

26. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. *Adv Drug Deliv Rev*. 2000;41(2):147–162.

27. Yang C, Gao S, Kjems J. Folic acid conjugated chitosan for targeted delivery of siRNA to activated macrophages in vitro and in vivo. *J Mater Chem B*. 2014;2(48):8608–8615.

28. Oliveira FdPP, Dalla Picola IP, Shi Q, et al. Synthesis and evaluation of diethylethylamine chitosan for gene delivery: composition effects on the in vitro transfection efficiency. *Nanotechnology*. 2013; 24(5):055101.

29. de Oliveira PR, Takaki M, Gorayeb TC, et al. Synthesis and evaluation of diethylethylamine chitosan on Aspergillus flavus. *Microbiol Res*. 2013;168(1):50–55.

30. Khachigian LM. Collagen antibody-induced arthritis. *Nat Protoc*. 2006;1(5):2512–2516.

31. Cho KC, Jeong JH, Chung HJ, et al. Folate receptor-mediated intracellular delivery of recombinant caspase-3 for inducing apoptosis. *J Control Release*. 2005;108(1):121–131.

32. Fernandes JC, Qiu X, Winnik FM, et al. Low molecular weight chitosan covalently conjugated with folate for siRNA delivery in vitro: optimization studies. *Int J Nanomedicine*. 2012;7:5833.

33. Yang C, Gao S, Dagnaes-Hansen F, Jakobsen M, Kjems J. Impact of PEG chain length on the physical properties and bioactivity of PEGylated chitosan/siRNA nanoparticles in vitro and in vivo. *ACS Appl Mater Interfaces*. 2017;9(4):12203–12216.

34. Malmo J, Sorgard H, Varum KM, Strand SP. siRNA delivery with chitosan nanoparticles: molecular properties favoring efficient gene silencing. *J Control Release*. 2012;158(2):261–268.

35. Tavakoli Naeini A, Soliman OY, Alameh MG, Lavertu M, Buschmann MD. Application of selected total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. *Arthritis Res Ther*. 2009;11(2):R41.

36. Shi Q, Bas DB, Su J, Sandor K, et al. Collagen antibody-induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency. *Arthritis Rheum*. 2012;64(12):3886–3896.

37. Kiraly K, Lavepeteliinen T, Arokosi J, et al. Application of selected cationic dyes for the semiquantitative estimation of glycosaminoglycans in histological sections of articular cartilage by microspectrophotometry. *Histoch J*. 1996;28(8):577–590.

38. Boileau C, Martel-Pelletier J, Caron J, et al. Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. *Arthritis Res Ther*. 2009;11(2):R41.

39. Ibanez L, Alcaraz MJ, Maicas N, et al. Downregulation of the inflammatory response by CORM-3 results in protective effects in a model of postmenopausal arthritis. *Calcif Tissue Int*. 2012;91(1):69–80.

40. Oestgaard S, Chouniard L, Doyle N, et al. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. *Osteoarthritis Cartilage*. 2006;14(7):670–679.

41. Ramprasth VR, Shanthi P, Sachandanam P. Curative effect of Semecarpus anacardium Linn. nut milk extract against adjuvant arthritis with special reference to bone metabolism. *Chem Biol Interact*. 2006; 160(3):183–192.

42. Romas E, Bakharevski O, Hards DK, et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. *Arthritis Rheum*. 2000;43(4):321.

43. Rojanarata T, Petchsangsai M, Opanasopit P, et al. Methylated N-(4-N,N-dimethylaminobenzyl) chitosan for novel effective gene carriers. *Eur J Pharm Biopharm*. 2008;70(1):207–214.

44. Liu X, Howard KA, Dong M, et al. The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. *Biomaterials*. 2007;28(6):1280–1288.

45. Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. *Adv Drug Deliv Rev*. 2004;56(8):1055–1058.

46. Turk MJ, Breur GJ, Widmer WR, et al. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. *Arthritis Rheum*. 2002;46(7):1947–1955.

47. Smolen JS, Aletaha D, Koelzer M, et al. New therapies for treatment of rheumatoid arthritis. *Lancet*. 2007;370(9602):1861–1874.

48. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30(4):339–353.

49. Komano Y, Tanaka M, Nakita T, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the registry of Japanese rheumatoid arthritis patients for longterm safety. *J Rheumatol*. 2011;38(7):1258–1264.

50. Komano Y, Yagi N, Onoue I, et al. Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis. *J Pharmacol Exp Ther*. 2012;340(1):109–113.

51. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. *J Bone Miner Res*. 2009;24(4):561–574.

52. Liu WC, Yen JF, Lang CL, et al. Bisphophonates in CKD patients with low bone mineral density. *Sci World J*. 2013;2013:837537.

53. Lehman MA, Kream J, Brogna D. Acid and alkaline phosphatase activity in the serum and syovial fluid of patients with arthritis. *J Bone Joint Surg Am*. 1964;46(8):1732–1738.

54. Seibel M. Molecular markers of bone turnover: biochemical, technical and analytical aspects. *Osteoporos Int*. 2000;11(18):S18–S29.

55. Swaminathan R. Biochemical markers of bone turnover. *Clinica Chimica Acta*. 2001;313(1):95–105.

56. Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. *Clin Chem*. 1996; 42(6 Pt 1):947–954.

57. Lian JB, Gundberg CM. Osteocalcin. Biochemical considerations and clinical applications. *Clin Orthop Relat Res*. 1988(226):267–291.

58. Goran H, Rudling M, Elinder CG, et al. Analysis of bone markers in clinical applications. *Osteoporos Int*. 2000;11(18):S18–S29.

59. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix GlA protein: vitamin K-dependent proteins in bone. *Physiol Rev*. 1989;69(3):990–1047.

60. Glowacki J, Rey C, Glimcher M, et al. A role for osteocalcin in osteoclast differentiation. *J Cell Biochem*. 1991;45(3):292–302.

61. Gundberg CM. Biochemical markers of bone formation. *Clin Lab Med*. 2000;20(3):489–501.

62. Díaz AE, Díaz MM, de la Piedra C, Rapado A. Lack of correlation between levels of osteocalcin and bone alkaline phosphatase in healthy control and postmenopausal osteoporotic women. *Horm Metab Res*. 1995;27(3):151–154.

63. Bille DD. Biochemical markers in the assessment of bone disease. *Am J Med*. 1997;103(5):427–436.

64. Jancikla AJ, Neustadt DH, Nakasato YR, et al. Serum tartrate-resistant acid phosphatase isofoms in rheumatoid arthritis. *Clinica Chimica Acta*. 2002;320(1):49–58.
68. Kawai VK, Stein CM, Perrien DS, Griffin MR. Effects of anti-tumor necrosis factor α (anti-TNF) agents on bone. *Curr Opin Rheumatol*. 2012;24(5):576.

69. Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. *Scientifica*. 2013;2013:125705.